Abstract
Heart failure with reduced ejection fraction (HFrEF) imposes a significant burden on patients and healthcare systems. Iron deficiency (ID) is common this patient population and places additional burden as ID in patients with HFrEF is associated with poor quality of life and increased risk of hospitalisation and mortality. The objective of this analysis was to estimate the cost consequence of introducing FCM for the treatment of ID in patients with HFrEF from the perspective of healthcare payers in Italy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
